Rare diseases
Investigational molecules
Locations
Topolova 748, 250 67 Klecany, Czechia
Narodni Ustav Dusevniho Zdravi in Klecany, Czechia specialises in clinical trials of conditions such as Major depression, Narcolepsy, Schizophrenia, Anxiety, and other specialisations. This site conducts important research.
The clinic at Narodni Ustav Dusevniho Zdravi is conducting studies on conditions such as multiple sclerosis, amyotrophic lateral sclerosis, and atypical Parkinsonian disorders including multiple system atrophy, progressive supranuclear palsy, and corticobasal syndrome. Trials aim to evaluate novel therapeutic approaches and assess safety of emerging treatments.
Emphasis on integrating advanced diagnostic techniques and patient‑centered outcomes.
Research at the site focuses on severe mental health illnesses such as major depressive disorder, treatment‑resistant depression, and treatment‑resistant schizophrenia. The objective is to test innovative compounds and psychedelic‑assisted therapies for rapid symptom relief and long‑term safety.
Collaboration with multidisciplinary teams ensures comprehensive evaluation of both efficacy and tolerability.
Clinical investigations include patients with chronic obstructive pulmonary disease who also suffer from depressive symptoms, exploring how mental health interventions can improve overall wellbeing.
The program leverages the clinic’s expertise in both pulmonary care and psychosocial support.
The institution is advancing analytical, diagnostic and therapeutic equipment to support trials across multiple disease areas, enabling precise measurement of treatment effects.
These tools are applied across neurodegenerative, psychiatric, and respiratory studies to enhance data quality.
Studies examine the underlying behavioral mechanisms and psychological phenomena associated with chronic illness, aiming to refine supportive interventions.
Findings inform personalized care pathways within the clinic’s multidisciplinary framework.
Clinical trials currently enrolling participants at this site.
Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2
CzechiaPhase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1
CzechiaStudy of evenamide as add-on treatment for patients with treatment-resistant schizophrenia not adequately controlled by current antipsychotic medications
CzechiaSafety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder
CzechiaLong-Term Study on the Safety and Effects of ALKS 2680 for Patients with Narcolepsy Type 1 and Type 2
CzechiaStudy on Psilocybin, Ketamine, and Midazolam for Treating Depression in Cancer Patients
CzechiaStudy of psilocybin therapy for psychological distress in patients with COPD, ALS, multiple sclerosis, or atypical Parkinson's disorders
CzechiaEfficacy of Etifoxine in Adults with Adjustment Disorder with Anxiety: A Randomized, Double‑Blind, Placebo‑Controlled Trial
CzechiaStudy on Long-Term Safety of Iclepertin for Patients with Schizophrenia Who Completed Previous Trials
CzechiaTesting Ulotaront Added to Antidepressants for Adults with Major Depressive Disorder Who Did Not Respond Well to Initial Treatment
CzechiaStudy on the Safety and Effectiveness of Aticaprant with Antidepressants for Adults and Elderly with Major Depressive Disorder
CzechiaStudy on Psilocybin, Ketamine, and Midazolam for Patients with Treatment-Resistant Depression
CzechiaGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
